Boltz raises $110M Series A as pharma usage of its AI drug design platform grows 50x
a16z · x · 2026-11-18
AI biomolecular design startup Boltz announced a $110M Series A led by Bessemer VP, with a16z doubling down.
- Molecular token usage grew 50x since June
- Deployed at 6 of the world's top 20 pharma companies
- The company positions AI intelligence as a "consumable reagent" for drug discovery that scientists can buy and use on demand
A landmark case of AI-for-Science commercialization in pharma.
Related event: AI drug design startup Boltz raises $110M Series A as usage surges 50x(10 posts)→
More from Venture
- Perplexity turns Anthropic's S-1 into an interactive 3D-chart explainer — jeffgrimes9 · 2026-11-18
- "Boltz is a biotech exponential" — molecular tokens up 50x since June — GabriCorso · 2026-11-18
- Boltz, the AI lab that moved from MIT to the UK, raises $110M — GabriCorso · 2026-11-18
- 49% of CIOs over token budget: Microsoft made AI cost control the product at Ignite — BenBajarin · 2026-11-18
- Industry figures congratulate Boltz on its $110M Series A — GabriCorso · 2026-11-18
- TSMC now demanding cash upfront to secure capacity as AI demand strains supply chain — ctjlewis · 2026-11-18